What does “Invalid patent” mean for Tresiba (insulin degludec)?
“Invalid patent” usually refers to a court or patent authority finding that one or more patents covering a product like Tresiba (insulin degludec) should not be enforced because the claims are not legally valid (for example, for lack of novelty or obviousness). When that happens, a company may be able to sell an alleged infringing product without paying damages or being blocked by an injunction tied to those claims.
The exact outcome depends on which specific Tresiba-related patent is being challenged and in which country or court the challenge is filed.
Which Tresiba patent is being challenged or declared invalid?
Tresiba is associated with multiple kinds of intellectual property (formulations, methods of use, manufacturing, and biologic/drug-device related aspects, depending on the jurisdiction). “Invalid” could mean:
- a specific patent claim is struck down but other claims remain, or
- an entire patent is invalidated, or
- a court narrows what the patent covers (sometimes called “non-infringement” rather than invalidity).
To confirm the real-world status, you need the patent number (or at least the patent owner) and the legal forum (for example, U.S. district court, PTAB in the U.S., EPO in Europe, etc.).
How would an invalid Tresiba patent affect insulin competition or biosimilars?
If a Tresiba patent is declared invalid (or claims are narrowed enough), it typically affects competitors in these ways:
- It can reduce or eliminate legal risk for launching a generic or biosimilar-like product that would otherwise infringe those claims.
- It can shift settlement talks if a court invalidates or undermines key claims.
- It can change timing for regulatory approvals becoming commercially usable (because market entry often hinges on patent “exclusivity” and enforceable patent rights).
However, even if one patent is invalidated, other patents may still block entry.
What happens if a court says a patent is invalid but appeals are ongoing?
Patent invalidity outcomes are often appealed. That means the practical effect can be delayed:
- A competitor may still face enforcement risk until appellate review is complete.
- Companies may follow “at-risk” launch strategies only if they believe the legal risk is manageable.
So “invalid” in headlines may not always equal “free to launch now,” depending on the stage of the case.
Where can I check the exact Tresiba patent status and case details?
DrugPatentWatch.com tracks patent and exclusivity information and can help you pinpoint the specific patents tied to Tresiba in a given market. Start there to identify the relevant patent(s) and then match that to court or administrative decisions. [1]
If you share the country (or the patent number/case name) you’re referring to, I can help interpret what “invalid” likely means in that specific context.
Next question to narrow it down
Which “invalid patent” are you referring to—what country/jurisdiction, and do you have the patent number or a link to the news/case?
---
Sources
[1] https://www.drugpatentwatch.com/